Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?

@article{Kingwell2009InterferonsAM,
  title={Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?},
  author={Elaine Kingwell and Helen Tremlett},
  journal={Expert review of neurotherapeutics},
  year={2009},
  volume={9 9},
  pages={1263-5}
}
Prior to the 1990s the mainstay of treatment for multiple sclerosis (MS) was symptomatic support and short courses of corticosteroids for relapses. Cytotoxic immunosuppressants were typically reserved for those with very active MS disease because the known risks of therapy-related adverse events typically out-weighed the benefits; thus these drugs were never licensed for use in MS. The first immunomodulatory therapies (IMDs) approved for treatment of relapsing–remitting and secondary… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Similar Papers

Loading similar papers…